ADMA Adma Biologics Inc

$ADMA I believe there is a significant disconnect between the current share price and the underlying value of the company. This disconnect is not necessarily due to this being a speculative investment, in my view. On the contrary, it looks to me like the price reflects a loss of faith in management's ability to correctly forecast growth. If there are buyers with deep pockets who still believe in the growth story of ASCENIV, I would consider the possibility of said buyers being interested in making an attempt to buy this business for a hefty, yet reasonable premium before the market learns if the growth story of ASCENIV is proven to be real in the coming quarters. Within the last 12 months, we've seen the share price at more than double the current levels, and the short report, in concert with a weakening environment for BIVIGAM, created a perfect storm-like scenario wherein the share price cratered. I believe the worst is behind ADMA. Good luck everyone!

$ADMA my belief is that the risk/reward ratio here is insanely favorable. If ASCENIV continues to grow at a similar rate, and if the production mix continues to increasingly favor ASCENIV, we should see a rerating of the stock based on revenues, profit, and very importantly, profit margin from ASCENIV.

$ADMA from ChatGPT: ASCENIV is already doing roughly a $400M+ annualized revenue run rate, is still growing ~24–26%, BIVIGAM caused most of the recent deterioration, corporate gross margins have reached ~70%, cash conversion has improved dramatically, and the stock is around $9–10.

$ADMA Q2 was a success, let's wait and see how next quarter goes and if buybacks continue. 👍

$ADMA with all the misses in cardio and muscle it’s great to have a cash generating , de risked asset (Asceniv)

$ADMA ….hmm, just a little bit of a trend up. Has it reached bottom? Time to buy back in? Sol what I had in low 20’s.

$ADMA Here’s how ADMA’s the board and senior management manage shareholder relations in order to drive shareholder value: - The IR function is non existent. It’s outsourced and calls are never answered nor messages returned. - The company doesn’t attend investor conferences like its peers and like almost all companies do. That’s where new investors are identified - The company does not go on non deal roadshows to attract new investors . Typically the 4 sell side firms that follow the company would gladly take management around to meet new and existing accounts . This is how many new shareholders come on board. - On earnings calls management limits the number of questions from mainly the sell sided analysts . They try to hurry through the call. Thats simply ridiculous. - None of the CEO and senior executives have bought shares at these price levels . That in itself says plenty.

$ADMA Federal securities class action lawsuits against biopharmaceutical companies typically take 2 to 4 years from initial filing to reach a final resolution (either a settlement, a dismissal, or trial). If the judge grants ADMA's motion to dismiss with prejudice, the case could end as early as mid-to-late 2027.

$ADMA feels like Adam is really content to stay silent and ride the market. He’s rolling off cash and stock buybacks are cheaper at these levels. Smart investors will determine when the bottom is in.

$ADMA looks like there a few healthcare conferences in September. Lets see if Adam attends one and starts to turn this ship around

$ADMA If you analyze the investors in detail on fintel.io, you’ll see that there have indeed been some interesting moves pointing toward activist tendencies.

$ADMA what is the floor on this stock? Fundamentally, it seems to be doing ok but keeps dropping. I'm not a long time owner - 2 years - but this is disheartening.

$ADMA wtf is this things problem??!! I'm going to kick Google assistant in the virtual nuts for this suggestion!

$ADMA Some still shorting the stock. CEO did some real damage to the company’s credibility during Bivigam fiasco. ADMA’s reported short interest rose to 22.68 million shares as of August 14, up from 21.92 million at July 31—an increase of about 765,000 shares, or 3.5%. Short interest now represents approximately 10.5% of the public float, with about 8 days to cover. The August 14 data were published on August 25, 2026.

$ADMA you should just short this with all the money you have then. Short your life savings.

$ADMA quite the swan dive since I sold. Chart says no reason to buy except maybe luck out with a bottom fish.